Several other analysts also recently issued reports on AMPH. TheStreet raised shares of Amphastar Pharmaceuticals from a c+ rating to a b- rating in a report on Friday, January 11th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, January 24th. Piper Jaffray Companies downgraded shares of Amphastar Pharmaceuticals from an overweight rating to a neutral rating and reduced their price target for the company from $24.00 to $23.00 in a report on Wednesday, March 13th. Finally, Needham & Company LLC downgraded shares of Amphastar Pharmaceuticals from a buy rating to a hold rating and set a $22.20 price target for the company. in a report on Wednesday, March 13th. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $23.73.
Shares of AMPH traded down $0.36 during mid-day trading on Friday, hitting $21.92. 115,500 shares of the company’s stock were exchanged, compared to its average volume of 182,926. Amphastar Pharmaceuticals has a twelve month low of $15.04 and a twelve month high of $25.43. The firm has a market cap of $998.26 million, a price-to-earnings ratio of 104.38 and a beta of 1.36. The company has a quick ratio of 1.35, a current ratio of 2.06 and a debt-to-equity ratio of 0.11.
In related news, EVP Rong Zhou sold 9,600 shares of the stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $22.76, for a total transaction of $218,496.00. Following the completion of the sale, the executive vice president now owns 66,707 shares in the company, valued at approximately $1,518,251.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jason B. Shandell sold 7,500 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $24.99, for a total transaction of $187,425.00. Following the sale, the insider now owns 175,818 shares of the company’s stock, valued at approximately $4,393,691.82. The disclosure for this sale can be found here. Insiders have sold a total of 73,614 shares of company stock valued at $1,597,609 over the last ninety days. 30.80% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Financial Gravity Wealth Inc. acquired a new stake in Amphastar Pharmaceuticals in the 1st quarter valued at about $43,000. Quadrant Capital Group LLC acquired a new stake in Amphastar Pharmaceuticals in the 1st quarter valued at about $53,000. Acadian Asset Management LLC acquired a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at about $63,000. First Quadrant L P CA bought a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at about $67,000. Finally, LS Investment Advisors LLC boosted its stake in shares of Amphastar Pharmaceuticals by 217.9% in the 4th quarter. LS Investment Advisors LLC now owns 3,522 shares of the company’s stock valued at $70,000 after purchasing an additional 2,414 shares during the last quarter. Hedge funds and other institutional investors own 47.43% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Further Reading: Asset Allocation and Your Retirement
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.